Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PIK3CA”

167 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 167 results

Large-scale testing (Phase 3)Looking for participantsNCT07207070
What this trial is testing

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Risen (Suzhou) Pharma Tech Co., Ltd. 312
Early research (Phase 1)Study completedNCT01613950
What this trial is testing

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

Who this might be right for
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
Novartis Pharmaceuticals 18
Large-scale testing (Phase 3)Looking for participantsNCT06757634
What this trial is testing

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Who this might be right for
Breast Cancer
Celcuity Inc 1,180
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439175
What this trial is testing

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT07543822
What this trial is testing

24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs

Who this might be right for
Vascular AnomaliesVascular AnomalyTIE2/PIK3CA Pathway Driven Vascular Anomalies
Children's Hospital of Philadelphia 61
Early research (Phase 1)Ended earlyNCT02961283
What this trial is testing

Study of ASN003 in Subjects With Advanced Solid Tumors

Who this might be right for
NeoplasmsMelanomaColorectal Neoplasm+1 more
Asana BioSciences 24
Testing effectiveness (Phase 2)Ended earlyNCT04216472
What this trial is testing

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8+19 more
M.D. Anderson Cancer Center 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT05090358
What this trial is testing

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Who this might be right for
Breast CancerBreast Cancer Stage IVMetastatic Breast Cancer
Memorial Sloan Kettering Cancer Center 15
Testing effectiveness (Phase 2)Ended earlyNCT04862143
What this trial is testing

Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 2
Not applicableLooking for participantsNCT07073755
What this trial is testing

Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd

Who this might be right for
Metastatic Breast CancerDrug ResistanceHormone Receptor-Positive Breast Cancer+3 more
Hunan Cancer Hospital 200
Not applicableEnded earlyNCT01346579
What this trial is testing

Biomarkers in Tissue Samples From Older Women With Breast Cancer

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 505
Not applicableNot Yet RecruitingNCT07543250
What this trial is testing

A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Who this might be right for
Breast Cancer
xuliang 100
Testing effectiveness (Phase 2)Ended earlyNCT03386162
What this trial is testing

SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer

Who this might be right for
Breast Cancer, PI3K, Alpelisib
UNICANCER 31
Early research (Phase 1)UnknownNCT04856371
What this trial is testing

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Haihe Biopharma Co., Ltd. 228
Testing effectiveness (Phase 2)Looking for participantsNCT05577754
What this trial is testing

Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)

Who this might be right for
Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)
Centre Hospitalier Universitaire Dijon 20
Large-scale testing (Phase 3)Study completedNCT03285802
What this trial is testing

Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation

Who this might be right for
Uterine Cancer
Greater Baltimore Medical Center 1
Large-scale testing (Phase 3)Study completedNCT01572727
What this trial is testing

The Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 416
Testing effectiveness (Phase 2)UnknownNCT04073680
What this trial is testing

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Who this might be right for
Breast CancerEndometrial CancerLung Cancer+2 more
Petra Pharma 60
Testing effectiveness (Phase 2)Study completedNCT02443818
What this trial is testing

Sirolimus Effect on Hypertrophic Syndromes Related Gene PIK3CA

Who this might be right for
Segmental Overgrowth Disorders Due to PIK3CA
Centre Hospitalier Universitaire Dijon 16
Post-approval studies (Phase 4)Study completedNCT05631795
What this trial is testing

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 40
Next Page